Neurogene Inc. DEF 14A: Executive Pay & Equity Awards Detailed
Ticker: NGNE · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1404644
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards, corporate-governance
TL;DR
Neurogene Inc. DEF 14A out: Executive pay & equity awards for 2024 detailed. Check out McMinn, Cochener, Drachman comp.
AI Summary
Neurogene Inc. filed a DEF 14A with the SEC on April 25, 2025, detailing executive compensation and corporate governance for the fiscal year ending December 31, 2024. The filing includes information on compensation for key individuals such as Dr. McMinn, Ms. Cochener, and Dr. Drachman, as well as details on equity awards granted and outstanding. The company, formerly known as Neoleukin Therapeutics, Inc., is based in New York.
Why It Matters
This filing provides crucial transparency into how Neurogene Inc. compensates its top executives and manages equity, which can influence investor decisions and company performance.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures about executive compensation and corporate governance, but can sometimes reveal changes or issues that impact investor confidence.
Key Numbers
- 2024 — Fiscal Year End (Period covered by the executive compensation and equity award details.)
- 20250425 — Filing Date (Date the DEF 14A was filed with the SEC.)
Key Players & Entities
- Neurogene Inc. (company) — Filer of the DEF 14A
- Neoleukin Therapeutics, Inc. (company) — Former name of Neurogene Inc.
- Dr. McMinn (person) — Executive/Director mentioned in compensation details
- Ms. Cochener (person) — Executive/Director mentioned in compensation details
- Dr. Drachman (person) — Executive/Director mentioned in compensation details
FAQ
What was the total compensation for Dr. McMinn in fiscal year 2024?
The filing indicates compensation details for Dr. McMinn for the fiscal year 2024, but specific dollar amounts are not provided in this excerpt.
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used to solicit proxies from shareholders for an annual meeting and provides detailed information on executive compensation, board of directors, and corporate governance.
When did Neurogene Inc. change its name from Neoleukin Therapeutics, Inc.?
Neurogene Inc. changed its name from Neoleukin Therapeutics, Inc. on August 12, 2019.
What type of awards are detailed in the filing for 2024?
The filing details equity awards granted, outstanding, and unvested, including their fair value at year-end for 2024.
Where is Neurogene Inc. headquartered?
Neurogene Inc. is headquartered at 535 W 24th Street, 5th Floor, New York, NY 10011.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 by Dr. McMinn regarding Neurogene Inc. (NGNE).